Robert D. Timmerman

Robert D. Timmerman, M.D., serves as Professor and Chair of Radiation Oncology and Professor of Neurosurgery at the University of Texas Southwestern Medical Center, holding the Effie Marie Cain Distinguished Chair in Cancer Therapy Research. His clinical focus centers on treating adult and pediatric brain tumors using advanced stereotactic techniques.

Dr. Timmerman's research portfolio demonstrates deep expertise in stereotactic body radiation therapy (SBRT/SABR), particularly through leadership in the PULSAR (Personalized Ultra-Fractionated Stereotactic Adaptive Radiotherapy) initiative. His work bridges radiation physics, immunotherapy, and AI-driven adaptive systems, with recent publications emphasizing biology-guided radiotherapy, multi-omics outcome prediction, and radio-immunotherapy synergies. Current investigations explore FLASH radiotherapy, PET-guided treatments, and real-time adaptive workflows using novel platforms like the RefleXion X1 system.

His publication trends reveal three dominant themes: (1) Technical innovation in adaptive radiotherapy (35% of recent work), focusing on CBCT-guided and PET-guided systems; (2) Radio-immunotherapy combinations (30%), particularly mathematical modeling of synergistic effects; (3) Clinical implementation of hypofractionated regimens (25%) across multiple cancer types. Notable projects include the VALOR phase 3 trial comparing lung cancer surgery to stereotactic radiotherapy and NRG Oncology/RTOG 0631 for spinal metastases.

• Fellow of the American Society for Radiation Oncology (FASTRO)
• Fellow of the American College of Radiology (FACR)

As national principal investigator for RTOG trials and leader of the Veterans Affairs Cooperative Studies Program Study 2005 (VALOR), Dr. Timmerman directs multiple multi-institutional grants evaluating stereotactic radiotherapy for early-stage lung cancer. His team collaborates extensively with physics and AI researchers to develop real-time adaptive systems, including the SCINTIX biology-guided platform. Current efforts focus on integrating circulating tumor DNA analysis with radiation response and optimizing risk-benefit ratios through Calculated Useful Trauma (CUT) frameworks.

Dr. Timmerman co-leads the PULSAR research consortium developing personalized ultra-hypofractionated regimens, with active projects spanning prostate, renal cell carcinoma, and brain metastases treatments. The team maintains close partnerships with medical physics and bioengineering departments to implement novel imaging and delivery systems.